(EMAILWIRE.COM, August 19, 2018 ) The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the market. On the other hand, high treatment cost for bleeding disorder treatment products coupled with limited reimbursement is expected to hinder the growth of this market during the forecast period.

Know More: https://www.marketsandmarkets.com/Market-Reports/bleeding-disorder-treatment-market-71198026.html

The global bleeding disorders treatment market is broadly classified by type and drug class. Based on type, the market is classified as hemophilia A, hemophilia B, vWD, and others. Hemophilia A is the largest segment and is projected to witness a healthy CAGR in forecast period. The growing number of patients suffering from hemophilia A, coupled with increasing awareness, and increasing R&D activities for development of novel products for treating hemophilia A by major pharmaceuticals are key drivers for this market segment.

Based on drug class, the bleeding disorders treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate during the forecast period. This increasing focus on developing recombinant factors due to their high efficiency in preventing bleeding episodes over plasma-derived products are driving their market demand.

The global bleeding disorders treatment market is dominated by North America, followed by Europe. North America will continue to dominate the global market in the forecast period. The high acceptance for prophylaxis treatment among all age groups in the U.S. is a key market driver in the region.

The key players in the bleeding disorders treatment market are are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).

Download FREE Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=71198026